Table 2.
Cox regression analyses of NT-proBNP for predicting MACEs according to glucose status at baseline
| Category | Crude HR (95% CI) | Adjusted HR (95% CI) |
|---|---|---|
| Overalla | ||
| LgNT-proBNP (per 1-SD) | 2.82 (2.21–3.60)‡ | 1.61 (1.35–1.91)‡ |
| Tertile 1 (< 92.5 pg/mL) | 1.00 (reference) | 1.00 (reference) |
| Tertile 2 (92.5-491.1 pg/mL) | 2.10 (1.45–3.03)‡ | 1.89 (1.24–2.86)† |
| Tertile 3 (> 491.1 pg/mL) | 3.24 (2.29–4.60)‡ | 2.65 (1.77–3.98)‡ |
| Normoglycemia | ||
| LgNT-proBNP (per 1-SD) | 1.32 (1.05–1.66)* | 1.12 (0.76–1.65) |
| Tertile 1 (< 65.5 pg/mL) | 1.00 (reference) | 1.00 (reference) |
| Tertile 2 (65.5-405.8 pg/mL) | 1.37 (0.77–2.44) | 1.31 (0.73–2.35) |
| Tertile 3 (> 405.8 pg/mL) | 1.65 (0.96–2.85) | 1.50 (0.83–2.71) |
| Pre-DM | ||
| LgNT-proBNP (per 1-SD) | 1.96 (1.54–2.50)‡ | 1.61 (1.23–2.12)‡ |
| Tertile 1 (< 101.8 pg/mL) | 1.00 (reference) | 1.00 (reference) |
| Tertile 2 (101.8–507.0 pg/mL) | 2.59 (1.45–4.64)* | 2.39 (1.25–4.55)† |
| Tertile 3 (> 507.0 pg/mL) | 3.64 (2.07–6.39)‡ | 2.56 (1.34–4.91)† |
| DM | ||
| LgNT-proBNP (per 1-SD) | 1.92 (1.52–2.42)‡ | 1.69 (1.30–2.21)‡ |
| Tertile 1 (< 110.6 pg/mL) | 1.00 (reference) | 1.00 (reference) |
| Tertile 2 (110.6-518.8 pg/mL) | 1.64 (1.11–2.75)* | 1.51 (1.04–2.20)* |
| Tertile 3 (> 518.8 pg/mL) | 2.60 (1.59–4.24)‡ | 2.34 (1.32–4.16)‡ |
The adjusted model included age, sex, hypertension, current smoking, systolic blood pressure, creatinine, low-density lipoprotein cholesterol, glycosylated hemoglobin, high sensitivity C-reactive protein, and baseline statin use
CI confidence interval, DM diabetes mellitus, HR hazard ratio, LgNT-proBNP log-transformed NT-proBNP, MACEs major adverse cardiovascular events, NT-proBNP N-terminal pro-B-type natriuretic peptide, Pre-DM prediabetes mellitus
aIn the overall population, the adjusted model included the above variables plus DM
*p < 0.05, †p < 0.01; ‡p < 0.001